The Chris Brown Connection

The draft recommendations announced today by NICE in the stand-in technology appraisal consultation document (ACD) suggest that Tyverb (lapatinib) should not be second-hand in the NHS, except in clinical trials.

“Given our involvement, it is burdensome to reference without the appearance of self stake, in any event we strongly in that the come to grief decision has been made for patients, doctors and the NHS,” said Simon Jose, Imprecise Manageress recompense GSK UK Pharmaceuticals. “For patients with ErbB2-out-and-out advanced breast cancer and who require few treatment options communistic, Tyverb offers real wait of slowing the cancer. We therefore balance wholly committed to working with the NHS and STRICT to make this innovative medicine available.”

Demonstrating the value of Tyverb (lapatinib)

In a pivotal clinical litigation which led to its EU licence, lapatinib, in grouping with capecitabine (Xeloda®), significantly increased the time it took for ErbB2-unqualified titty cancer to worsen (’time to ascension - TTP’) compared with using capecitabine alone.1

In its draft guidance, NICE acknowledges that lapatinib is a clinically powerful option and notes that lapatinib increased by capecitabine was associated with improved TTP and progression-free survival.

Lapatinib, in compound with capecitabine, is the solitary treatment option which is licensed for reason in patients with this aggressive put together of advanced breast cancer, who drink limited treatment options remaining if their cancer has continued to grow despite treatment with standard chemotherapies, and trastuzumab (Herceptin®) for advanced sickness.

GSK has till the end of time acknowledged that the pharmaceutical industry has a responsibility to work together in demonstrating our medicines are cost-gear within the SUPERB framework to achieve a positive outcome for patients and their families.

In recognition that the firstly ACD from NICE did not consider lapatinib to be rate effective in treating this dogged population, GSK proposed an innovative unswerving access schedule, where GSK would bear the expense of lapatinib for all eligible patients, object of up to the start 12 weeks of treatment. The NHS would commence payment only for the patients who pick up to receive clinical benefit beyond 12 weeks. This programme was designed to produce access to all eligible patients and deliver expense-effectiveness at a threshold that should have planned been OK to POLITE.

The cost-effectiveness of lapatinib plus capecitabine was supported by a resemblance to trastuzumab-containing regimens, and capecitabine singular, representing the established treatment regimens in NHS clinical technique. Whilst NICE accepted that trastuzumab is to a large used following advance of the disease, NICE suggested it was unlikely to be payment-effectual, and therefore did not assent to trastuzumab as a valid comparator.

The way in which the verdict has been made makes it simple nit-picking to ever demonstrate the cost effectiveness of lapatinib in this patient population, even in light of the proposed patient access lay out.

Implications for patients if praise is upheld

COMMENDABLE has acknowledged that lapatinib is a clinically effective alternative associated with improved over and over again to development and intensification-unchain survival. GSK is concerned that patients in the UK will not receive these benefits if the another ACD draft advocacy is adopted.

The EXACT draft recommendation would upshot in patients in the UK being disadvantaged compared to respective other European countries that have already acknowledged the value of lapatinib and are reimbursing the medicine, including Austria, Denmark, Germany, Greece, Ireland, Luxembourg and Switzerland.

GSK will continue to drill equal with NICE to demonstrate the cost-effectiveness of Tyverb in all eligible patients by seeking to validate trastuzumab as a legitimate comparator. Deplete of Tyverb plus capecitabine will at long last reduce the costs to the UK health system compared to the established but unlicensed clinical practice of continuing to use trastuzumab at one time a patient’s sickness has progressed.

About Tyverb

– Tyverb, in combination with capecitabine, is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress ErbB2 (HER2). Patients should have radical disease following prior therapy which must include anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. 2

– The most banal adverse events associated with lapatinib plus capecitabine were diarrhoea, rash, nausea, vomiting, fatigue and near-foot syndrome.1,2 Diarrhoea and rash were more common with the combination whilst the prevalence of hand-foot syndrome was similar between the two treatment groups. 2

– A decrease in left ventricular ejection fraction (LVEF) was reported by 2.5% of patients receiving lapatinib benefit capecitabine vs. 1% of patients on capecitabine alone. 2

– Hepatobiliary events (mainly raised liver enzymes and/or bilirubin levels) have been reported commonly in association with lapatinib with the addition of capecitabine remedial programme. 2

– Lapatinib has also been associated with reports of pulmonary toxicity. 2

– Healthcare professionals should refer to the lapatinib Summary of Characteristics (SmPC) for full prescribing information, including warnings and precautions. 2

GlaxoSmithKline - one of the world’s pre-eminent experiment with-based pharmaceutical and healthcare companies - is committed to improving the trait of compassionate survival by enabling people to do more, pet superior and live longer. In search further intelligence please stopover http://www.gsk.com

Tyverb® is a registered trademark of the GlaxoSmithKline group of companies. Herceptin® and Xeloda® are registered trademarks of F. Hoffmann-La Roche Ltd.

References

1. Cameron D, Casey M, Journos M, et al. A aspect III randomised comparison of lapatinib benefit capecitabine versus capecitabine alone in women with advanced mamma cancer that has progressed on tratsuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Favour 2008; epub ahead of print publication.
2. Tyverb® (lapatinib) Summary of Product Characteristics.

View drug information on Herceptin; Xeloda.